RHYTHM PHARMACEUTICALS, INC. Research and Development Expense
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Research and Development Expense of $43.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $43.43M, a 2.65% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $41.73M, a 12.85% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $42.03M, a 2.10% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $46.03M, a 21.34% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $167.34M, a 29.68% decline from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $237.96M, a 76.33% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $134.95M, a 24.23% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $108.63M, a 4.32% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.43M 10-Q · filed 2026-08-04 | $85.15M 10-Q · filed 2026-08-04 | $127.19M derived: sum of 3 quarters · filed 2026-08-04 | $173.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $41.73M 10-Q · filed 2026-05-05 | $83.76M derived: sum of 2 quarters · filed 2026-05-05 | $129.78M derived: sum of 3 quarters · filed 2026-05-05 | $172.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $42.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $88.06M derived: sum of 2 quarters · filed 2026-02-26 | $130.37M derived: sum of 3 quarters · filed 2026-08-04 | $167.34M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.03M 10-Q · filed 2025-11-04 | $88.33M derived: sum of 2 quarters · filed 2026-08-04 | $125.31M 10-Q · filed 2025-11-04 | $166.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $42.31M 10-Q · filed 2026-08-04 | $79.28M 10-Q · filed 2026-08-04 | $120.45M derived: sum of 3 quarters · filed 2026-08-04 | $158.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $36.97M 10-Q · filed 2026-05-05 | $78.14M derived: sum of 2 quarters · filed 2026-05-05 | $116.07M derived: sum of 3 quarters · filed 2026-05-05 | $146.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $41.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.10M derived: sum of 2 quarters · filed 2026-02-26 | $109.29M derived: sum of 3 quarters · filed 2026-02-26 | $237.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | $37.93M 10-Q · filed 2025-11-04 | $68.13M derived: sum of 2 quarters · filed 2025-11-04 | $196.79M 10-Q · filed 2025-11-04 | $226.68M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.19M 10-Q · filed 2025-08-05 | $158.86M 10-Q · filed 2025-08-05 | $188.75M derived: sum of 3 quarters · filed 2026-02-26 | $222.32M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $128.66M 10-Q · filed 2025-05-07 | $158.56M derived: sum of 2 quarters · filed 2026-02-26 | $192.13M derived: sum of 3 quarters · filed 2026-02-26 | $225.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $29.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $63.46M derived: sum of 2 quarters · filed 2026-02-26 | $97.00M derived: sum of 3 quarters · filed 2026-02-26 | $134.95M 10-K · filed 2026-02-26 |
| 2023-09-30 | $33.57M 10-Q · filed 2024-11-06 | $67.11M derived: sum of 2 quarters · filed 2024-11-06 | $105.06M 10-Q · filed 2024-11-06 | $128.61M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $33.54M 10-Q · filed 2024-08-06 | $71.49M 10-Q · filed 2024-08-06 | $95.04M derived: sum of 3 quarters · filed 2025-02-28 | $116.15M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $37.95M 10-Q · filed 2024-05-07 | $61.49M derived: sum of 2 quarters · filed 2025-02-28 | $82.61M derived: sum of 3 quarters · filed 2025-02-28 | $114.06M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $23.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $44.66M derived: sum of 2 quarters · filed 2025-02-28 | $76.12M derived: sum of 3 quarters · filed 2025-02-28 | $108.63M 10-K · filed 2025-02-28 |
| 2022-09-30 | $21.12M 10-Q · filed 2023-11-08 | $52.57M derived: sum of 2 quarters · filed 2023-11-08 | $85.08M 10-Q · filed 2023-11-08 | $116.66M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $31.46M 10-Q · filed 2023-08-01 | $63.97M 10-Q · filed 2023-08-01 | $95.54M derived: sum of 3 quarters · filed 2024-02-29 | $123.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $32.51M 10-Q · filed 2023-05-02 | $64.08M derived: sum of 2 quarters · filed 2024-02-29 | $91.62M derived: sum of 3 quarters · filed 2024-02-29 | $116.73M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $31.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $59.11M derived: sum of 2 quarters · filed 2024-02-29 | $84.22M derived: sum of 3 quarters · filed 2024-02-29 | $104.13M 10-K · filed 2024-02-29 |
| 2021-09-30 | $27.54M 10-Q · filed 2022-11-08 | $52.64M derived: sum of 2 quarters · filed 2022-11-08 | $72.55M 10-Q · filed 2022-11-08 | $94.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $25.10M 10-Q · filed 2022-08-03 | $45.02M 10-Q · filed 2022-08-03 | $66.97M derived: sum of 3 quarters · filed 2023-03-01 | $89.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $19.91M 10-Q · filed 2022-05-03 | $41.87M derived: sum of 2 quarters · filed 2023-03-01 | $64.86M derived: sum of 3 quarters · filed 2023-03-01 | $87.86M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $21.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $44.95M derived: sum of 2 quarters · filed 2023-03-01 | $67.95M derived: sum of 3 quarters · filed 2023-03-01 | $90.45M 10-K · filed 2023-03-01 |
| 2020-09-30 | $23.00M 10-Q · filed 2021-11-02 | $45.99M derived: sum of 2 quarters · filed 2021-11-02 | $68.50M 10-Q · filed 2021-11-02 | $93.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $23.00M 10-Q · filed 2021-08-03 | $45.50M 10-Q · filed 2021-08-03 | $70.31M derived: sum of 3 quarters · filed 2022-03-01 | $96.88M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $22.50M 10-Q · filed 2021-05-03 | $47.31M derived: sum of 2 quarters · filed 2022-03-01 | $73.89M derived: sum of 3 quarters · filed 2022-03-01 | $109.19M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $24.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $51.38M derived: sum of 2 quarters · filed 2022-03-01 | $86.69M derived: sum of 3 quarters · filed 2022-03-01 | $109.45M 10-K · filed 2022-03-01 |
| 2019-09-30 | $26.57M 10-Q · filed 2020-11-02 | $61.88M derived: sum of 2 quarters · filed 2020-11-02 | $84.64M 10-Q · filed 2020-11-02 | $103.40M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $35.31M 10-Q · filed 2020-08-03 | $58.07M 10-Q · filed 2020-08-03 | $76.83M derived: sum of 3 quarters · filed 2021-03-01 | $87.54M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $22.76M 10-Q · filed 2020-05-04 | $41.52M derived: sum of 2 quarters · filed 2021-03-01 | $52.23M derived: sum of 3 quarters · filed 2021-03-01 | $60.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $18.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $29.47M derived: sum of 2 quarters · filed 2021-03-01 | $38.05M derived: sum of 3 quarters · filed 2021-03-01 | $50.34M 10-K · filed 2021-03-01 |
| 2018-09-30 | $10.71M 10-Q · filed 2019-11-01 | $19.29M derived: sum of 2 quarters · filed 2019-11-01 | $31.57M 10-Q · filed 2019-11-01 | $38.23M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $8.58M 10-Q · filed 2019-07-29 | $20.87M 10-Q · filed 2019-07-29 | $27.52M derived: sum of 3 quarters · filed 2020-03-02 | $33.49M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $12.29M 10-Q · filed 2019-05-03 | $18.94M derived: sum of 2 quarters · filed 2020-03-02 | $24.91M derived: sum of 3 quarters · filed 2020-03-02 | $30.31M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $12.62M derived: sum of 2 quarters · filed 2020-03-02 | $18.02M derived: sum of 3 quarters · filed 2020-03-02 | $22.89M 10-K · filed 2020-03-02 |
| 2017-09-30 | $5.97M 10-Q · filed 2018-11-09 | $11.37M derived: sum of 2 quarters · filed 2018-11-09 | $16.24M 10-Q · filed 2018-11-09 | $21.87M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-06-30 | $5.40M 10-Q · filed 2018-08-08 | $10.27M 10-Q · filed 2018-08-08 | $15.90M derived: sum of 3 quarters · filed 2019-03-08 | $21.32M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-03-31 | $4.87M 10-Q · filed 2018-05-14 | $10.50M derived: sum of 2 quarters · filed 2019-03-08 | $15.92M derived: sum of 3 quarters · filed 2019-03-08 | |
| 2016-12-31 | $5.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $11.05M derived: sum of 2 quarters · filed 2019-03-08 | $19.59M 10-K · filed 2019-03-08 | |
| 2016-09-30 | $5.42M 10-Q · filed 2017-11-14 | $13.96M 10-Q · filed 2017-11-14 | ||
| 2015-12-31 | $7.15M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |